RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Questions People Actually Ask
Direct, citation-anchored answers about GHK-Cu, KPV, semaglutide, and tirzepatide — straight from the published record, not from a marketing page.
What does a GHK-Cu peptide do?
GHK-Cu is a copper-binding tripeptide that stimulates skin fibroblasts to produce collagen, elastin, and other structural proteins, while also suppressing inflammatory signaling and altering expression of roughly 31.2% of human genes at a meaningful threshold in laboratory gene-expression analyses [2]. Its best-documented practical effect is topical: increasing collagen production in the majority of treated subjects in small controlled studies, alongside modest improvements in skin texture and fine lines [1][4]. It is used almost entirely as a topical cosmetic ingredient; systemic or injectable use is unapproved and unstudied in humans.
What is GHK-Cu and how does it work?
GHK-Cu is the tripeptide glycyl-histidyl-lysine bound to a copper ion, occurring naturally in the body and declining in concentration with age [4]. It works by acting as a copper chaperone and cell-signaling molecule: at very low concentrations it drives dermal fibroblasts to make more collagen, elastin, and glycosaminoglycans, rebalances the enzymes that break down skin's structural matrix, and suppresses inflammatory (NF-kB) signaling at the gene level [2].
Is GHK-Cu peptide really anti-aging?
The honest answer is: modestly, and mostly topically. Small controlled human trials show real improvements in measures like collagen synthesis, skin laxity, and fine lines when GHK-Cu is applied to skin — in one comparison, topical GHK-Cu improved collagen production in about 70% of treated subjects versus 50% for vitamin C and 40% for retinoic acid [1][4]. A related combination formulation also produced a statistically significant increase in hair count in a 45-person trial [3]. What is not supported by controlled evidence is the sweeping systemic anti-aging and injectable-use claims made about it in some marketing — those go well beyond what the topical trial data actually demonstrates.
What is the difference between GHK and GHK-Cu?
GHK is the plain tripeptide (glycine-histidine-lysine) on its own. GHK-Cu is that same tripeptide bound to a copper ion. The copper coordination is not incidental — most of GHK-Cu's documented tissue-remodeling activity in laboratory studies depends on the copper being properly bound, and the free peptide without copper does not reproduce key effects seen in cell studies. In practice, almost all the human research and commercial products described as "copper peptide" refer specifically to GHK-Cu, not plain GHK.
What is KPV peptide?
KPV is a tripeptide — lysine, proline, valine — that makes up the tail end (residues 11 to 13) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains alpha-MSH's anti-inflammatory signaling without the hormone's pigment-darkening effect, which is why researchers study it separately from the parent hormone [10]. There is no published human clinical trial of KPV; it exists only as a laboratory research chemical.
What does KPV peptide do?
In cell and animal studies, KPV suppresses inflammatory signaling — specifically the NF-kB and MAP-kinase pathways — and reduces production of pro-inflammatory cytokines. In the gut, it is taken up directly by inflamed intestinal tissue through a transporter called PepT1, and in mouse models of colitis it reduced inflammation, sped recovery, and lowered markers of tissue damage [8][9]. All of this evidence comes from cell cultures and mice; none of it has been confirmed in a human trial.
What is KPV peptide used for?
In research settings, KPV is studied as a candidate anti-inflammatory agent for inflammatory bowel disease, tested almost exclusively in mouse models of colitis. Recent work has focused heavily on delivery: targeted nanoparticle formulations that carry KPV directly to inflamed gut tissue have improved outcomes over free KPV in animal studies [6][7]. It is not approved or studied for any use in humans, and it is sold only as a laboratory research chemical, not a supplement or medicine.
What is KPV peptide good for?
Based on the published research, KPV shows anti-inflammatory activity in laboratory and animal models of gut inflammation specifically — reducing colitis severity, restoring gut-lining integrity, and lowering inflammatory markers in mice [6][7][9]. A broader 2008 review situates related melanocortin tripeptides as protective across several inflammatory animal models beyond the gut [10]. None of that has been demonstrated in a human trial, so any claim that KPV is "good for" a particular human condition outruns the current evidence.
What is semaglutide?
Semaglutide is a synthetic peptide that mimics and outlasts the natural gut hormone GLP-1. It is FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with existing cardiovascular disease and overweight or obesity, and, since 2025, a form of fatty liver disease. It is given as a once-weekly injection or a once-daily oral tablet. It is a prescription medicine, not a research-only compound.
What is semaglutide used for?
Its FDA-approved uses include lowering blood sugar in type 2 diabetes, reducing body weight in chronic weight management, and reducing cardiovascular risk in adults with established cardiovascular disease and overweight or obesity [13]. It has also been studied for reducing kidney-disease progression in people with type 2 diabetes and chronic kidney disease, where it lowered a composite of major kidney outcomes by 24% [12], and for weight loss specifically, where it produced roughly 14.9% mean body-weight loss over 68 weeks in a major trial [14].
How does semaglutide work?
Semaglutide activates GLP-1 receptors in the pancreas, where it boosts insulin release only when blood sugar is elevated and suppresses the hormone that raises blood sugar, and in the stomach, where it slows emptying. Its weight effect is driven mainly by the brain: it reaches appetite-control circuits in the hypothalamus and brainstem, activating neurons that signal fullness and quieting the ones that drive hunger, which reduces food intake and changes food preference without necessarily lowering how much energy the body burns [16].
How does semaglutide work for weight loss?
The weight-loss effect comes primarily from reduced food intake driven by central appetite circuits rather than from any direct fat-burning action. In rodent studies, semaglutide's action on the hypothalamic arcuate nucleus and the brainstem area postrema reduced food intake and shifted food preference while energy expenditure stayed roughly the same [16]. In humans, this translated to a 14.9% mean body-weight reduction over 68 weeks in a landmark trial versus 2.4% with placebo [14] — though a later head-to-head trial found the dual-receptor peptide tirzepatide produced still greater weight loss than semaglutide over 72 weeks [11].
What is tirzepatide?
Tirzepatide is a synthetic peptide that activates two gut-hormone receptors at once, GIP and GLP-1, rather than the single GLP-1 receptor that semaglutide targets. It is FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity, given as a once-weekly injection [18].
How does tirzepatide work?
By engaging both the GIP and GLP-1 receptors, tirzepatide boosts glucose-dependent insulin release, suppresses the hormone that raises blood sugar, and slows stomach emptying — the shared GLP-1 pharmacology that drives appetite suppression and its gastrointestinal side effects. The added GIP-receptor arm is thought to contribute incrementally to the greater weight loss observed compared with single-receptor GLP-1 therapy, though the precise mechanistic split between the two receptors is still being studied [18].
What does tirzepatide do in the body?
In the pancreas, it increases insulin release only when blood sugar is elevated and suppresses glucagon, improving blood-sugar control with low risk of hypoglycemia when used alone. In the gut, it slows stomach emptying, contributing to prolonged fullness and to nausea as a side effect. In the brain, it acts on the same appetite-regulating hypothalamic circuits as semaglutide to reduce hunger and food-seeking behavior. In a major 72-week trial, this combination produced mean weight loss of up to 20.9% at the highest dose tested, versus 3.1% with placebo [20].
What is tirzepatide used for?
Tirzepatide's FDA-approved uses are type 2 diabetes (first approved May 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity [18]. In direct clinical comparison, it produced greater blood-sugar and weight improvements than semaglutide 1 mg in a diabetes trial [21], and greater weight loss than semaglutide's top dose in a dedicated head-to-head obesity trial [11].